AC-203
AC-203 reduces the activity and expression of pro-inflammatory cytokines, particularly IL-1β, TNF-α, and TGF-β. It also inhibits the activity of iNOS and the production of nitric oxide.
Epidermolysis Bullosa Simplex
Preclinical
Phase I
Phase II
Phase III
NDA
Bullous Pemphigoid
Preclinical
Phase I
Phase II
Phase III
NDA
AC-1101
AC-1101 is a patented gel formulation whose active ingredient is a small-molecule Janus kinase (JAK) inhibitor, and it can be used to treat autoimmune inflammatory skin diseases.
Granuloma Annulare
Preclinical
Phase I
Phase II
Phase III
NDA
Vitiligo
Preclinical
Phase I
Phase II
Phase III
NDA
Atopic Dermatitis
Preclinical
Phase I
Phase II
Phase III
NDA
NORA520
NORA520 which is a prodrug of brexanolone is an innovative therapeutic candidate developed for the treatment of postpartum depression (PPD) and major depressive disorder (MDD).
Postpartum Depression, PPD
Preclinical
Phase I
Phase II
Phase III
NDA
Major Depressive Disorder, MDD
Preclinical
Phase I
Phase II
Phase III
NDA